Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Acute Heart Failure Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Acute Heart Failure Overview | 8 | 1 |
| Acute Heart Failure Therapeutics under Development by Companies | 9 | 1 |
| Acute Heart Failure Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Acute Heart Failure Products under Development by Companies | 13 | 1 |
| Acute Heart Failure Companies Involved in Therapeutics Development | 14 | 8 |
| Amgen Inc. | 14 | 1 |
| Capricor Therapeutics, Inc. | 15 | 1 |
| Eli Lilly and Company | 16 | 1 |
| Lee's Pharmaceutical Holdings Limited | 17 | 1 |
| Novartis AG | 18 | 1 |
| Ono Pharmaceutical Co., Ltd. | 19 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 20 | 1 |
| Trevena, Inc. | 21 | 1 |
| Acute Heart Failure Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 24 |
| cenderitide Drug Profile | 31 | 3 |
| istaroxime Drug Profile | 34 | 2 |
| omecamtiv mecarbil MR Drug Profile | 36 | 7 |
| ONO-4232 Drug Profile | 43 | 1 |
| PB-1046 Drug Profile | 44 | 2 |
| ruboxistaurin Drug Profile | 46 | 2 |
| serelaxin Drug Profile | 48 | 4 |
| TRV-120023 Drug Profile | 52 | 1 |
| ularitide Drug Profile | 53 | 2 |
| Acute Heart Failure Dormant Projects | 55 | 1 |
| Acute Heart Failure Discontinued Products | 56 | 1 |
| Acute Heart Failure Product Development Milestones | 57 | 12 |
| Featured News &Press Releases | 57 | 1 |
| Dec 11, 2015: Cardiorentis' Ularitide Receives FDA Fast Track Designation for the Treatment of Acute Decompensated Heart Failure | 57 | 1 |
| May 22, 2015: Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure | 57 | 1 |
| Oct 16, 2014: Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide | 58 | 1 |
| Oct 09, 2014: Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation | 58 | 1 |
| May 23, 2014: Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure | 59 | 1 |
| May 16, 2014: FDA issues Complete Response Letter for RLX030 for acute heart failure | 59 | 1 |
| Mar 27, 2014: Novartis to work with FDA on path forward for RLX030 for acute heart failure following Advisory Committee outcome | 60 | 1 |
| Mar 25, 2014: FDA Staff Says Novartis Serelaxin Shouldn t Be Approved | 60 | 1 |
| Jan 24, 2014: Novartis Europharm's Reasanz Receives CHMP Negative Opinion | 61 | 1 |
| Jan 24, 2014: Novartis to request re-examination of serelaxin in acute heart failure for conditional marketing authorization in EU | 62 | 1 |
| Dec 02, 2013: Paladin Announces Filing of New Drug Submission for RLX030 (Serelaxin) | 63 | 1 |
| Sep 03, 2013: Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil | 63 | 2 |
| Sep 02, 2013: Novartis' serelaxin improved symptoms and mortality across multiple subgroups of patients with acute heart failure | 65 | 1 |
| Jun 21, 2013: Novartis's Serelaxin Receives FDA Breakthrough Therapy Designation For Acute Heart Failure | 66 | 1 |
| Mar 18, 2013: Cytokinetics Announces Update To Heart Failure Program | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |